RxDoctor Payments Data

Sam Cohlmia, MD

Ophthalmology · Wichita, KSNPI 1780641878

Payments from drug & device makers

$803in general payments, 2019–2025

Across 21 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$275
  • Carl Zeiss Meditec USA, Inc.$157
  • AbbVie$137
  • Apellis Pharmaceuticals, Inc.$122
  • Bausch & Lomb Americas Inc.$22
  • Sight Sciences, Inc.$22
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$78398%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$803 in reported general payments places this provider in the 35th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$276,183
Medicare patients
752
Services billed
2,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost72$30,674
RestasisCyclosporine32$19,528
CombiganBrimonidine Tartrate/Timolol84$19,498
SimbrinzaBrinzolamide/Brimonidine Tart29$8,575
Prednisolone Acetate307$7,850
MoxifloxacinMoxifloxacin Hcl268$7,118
Travoprost47$5,168
Ketorolac Tromethamine283$3,879
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$3,640
Latanoprost391$2,710
Timolol Maleate125$1,508
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$992
Brimonidine Tartrate67$395
Dorzolamide Hcl29$388
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$137$69,700188 claims
AlconSimbrinza$275$8,57529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →